GlobeStar Therapeutics Corp Overview
Industry: Biotechnology
Sector: Healthcare
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. The company was incorporated in 2016 and is headquartered in Richland, Washington.
GlobeStar Therapeutics Corp is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review GlobeStar Therapeutics Corp in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
GlobeStar Therapeutics Corp Competitors
GlobeStar Therapeutics Corp operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans